Federal Court Denies Request to Block Amgen, Allergan From Marketing Two Oncology Biosimilars

Drug Industry Daily
A federal judge in Delaware denied requests from Genentech to block the launch of biosimilars for its blockbuster treatments Avastin (bevacizumab) and Herceptin (trastuzumab). Following the court’s decision, Amgen and Allergan announced their products Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns) were available for sale.

To View This Article:


Subscribe To Drug Industry Daily